{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"MDM2, a ubiquitin ligase and p53 inhibitor, is amplified in a diverse range of cancers including well-differentiated liposarcomas.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"08/01/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[]
    },
    "description":"",
    "knownEffect":"Unknown"
  },
  "oncogenic":"Unknown",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"L321Ffs*52",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":4193,
    "hgvs":null,
    "hugoSymbol":"MDM2",
    "id":null,
    "proteinEnd":319,
    "proteinStart":319,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The biologic significance of the MDM2 L321Ffs*52 mutation is unknown (last reviewed 08/01/2017).",
  "vus":true
}